Literature DB >> 17377932

Weibull prediction of event times in clinical trials.

Gui-shuang Ying1, Daniel F Heitjan.   

Abstract

In clinical trials with interim analyses planned at pre-specified event counts, one may wish to predict the times of these landmark events as a tool for logistical planning. Currently available methods use either a parametric approach based on an exponential model for survival (Bagiella and Heitjan, Statistics in Medicine 2001; 20:2055) or a non-parametric approach based on the Kaplan-Meier estimate (Ying et al., Clinical Trials 2004; 1:352). Ying et al. (2004) demonstrated the trade-off between bias and variance in these models; the exponential method is highly efficient when its assumptions hold but potentially biased when they do not, whereas the non-parametric method has minimal bias and is well calibrated under a range of survival models but typically gives wider prediction intervals and may fail to produce useful predictions early in the trial. As a potential compromise, we propose here to make predictions under a Weibull survival model. Computations are somewhat more difficult than with the simpler exponential model, but Monte Carlo studies show that predictions are robust under a broader range of assumptions. We demonstrate the method using data from a trial of immunotherapy for chronic granulomatous disease. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 17377932     DOI: 10.1002/pst.271

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  6 in total

1.  Bayesian modeling and prediction of accrual in multi-regional clinical trials.

Authors:  Yi Deng; Xiaoxi Zhang; Qi Long
Journal:  Stat Methods Med Res       Date:  2014-11-03       Impact factor: 3.021

Review 2.  Do immune checkpoint inhibitors need new studies methodology?

Authors:  Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Cure modeling in real-time prediction: How much does it help?

Authors:  Gui-Shuang Ying; Qiang Zhang; Yu Lan; Yimei Li; Daniel F Heitjan
Journal:  Contemp Clin Trials       Date:  2017-05-22       Impact factor: 2.226

4.  End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.

Authors:  Antje Hoering; Brian Durie; Hongwei Wang; John Crowley
Journal:  Future Oncol       Date:  2017-04-11       Impact factor: 3.404

5.  Predicting analysis times in randomized clinical trials with cancer immunotherapy.

Authors:  Tai-Tsang Chen
Journal:  BMC Med Res Methodol       Date:  2016-02-01       Impact factor: 4.615

6.  Challenges of evaluating immunotherapy efficacy in solid tumors.

Authors:  Rilan Bai; Wenqian Li; Nawen Du; Jiuwei Cui
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.